Connect with us

Technology

Brainomix and Boehringer Ingelheim Advance Strategic Partnership in Pulmonary Fibrosis

Published

5 months ago

on

The two companies are broadening their partnership, building on strong results seen in the initial phase which demonstrated e-Lung’s potential to enable earlier diagnosis of progressive pulmonary fibrosis (PPF). Findings from the REVISE-PPF study will be presented at the American Thoracic Society (ATS) International Conference in Orlando, May 15-20, 2026.The next phase, PROGRESS-PPF, a prospective multicenter study, will focus on generating evidence of e-Lung’s clinical impact at scale, with deployments of e-Lung planned at numerous sites across the US.

OXFORD, England and CHICAGO, May 12, 2026 /PRNewswire/ — Brainomix, a global leader and pioneer of AI-powered imaging tools in lung fibrosis and stroke, today announced an expansion of its partnership with Boehringer Ingelheim, the leading biopharmaceutical company providing therapeutic options for interstitial lung disease (ILD), to improve the care of patients with progressive pulmonary fibrosis (PPF).

Patients with Interstitial Lung Diseases (ILD) may progress to PPF, a condition marked by irreversible lung damage and increased risk of early mortality. Without treatment, patients may have a lifespan as short as five years1, yet many still endure long delays – often years – before receiving a diagnosis2. Early diagnosis and intervention can play a major role in a patient’s prognosis, but determining which patients are eligible for treatment based on imaging remains challenging, even for experienced specialists.

Brainomix e-Lung is an FDA-cleared, AI-driven imaging software platform that automatically detects and quantifies abnormalities on thoracic CT scans, helping clinicians more easily identify changes, including subtle deterioration across multiple timepoints. Built on proprietary technology, e-Lung has been clinically validated to measure lung features associated with interstitial lung diseases (ILD).

Results from REVISE-PPF, a retrospective research study conducted with the University of Chicago, Weill Cornell Medical Center, and the University of Alabama at Birmingham, will be presented by Dr. Anna Podolanczuk (Weill-Cornell) at an ATS session on Sunday, May 17th. The study demonstrated that e-Lung was able to stratify patients at risk of PPF from a baseline CT and identified patients with radiologic evidence of PPF up to 28 months earlier than local clinical diagnoses.

This next phase of the Brainomix–Boehringer Ingelheim partnership aims to advance the work further, centered around a prospective, mixed-methods study, PROGRESS-PPF. Conducted across multiple sites in the US, it will generate both quantitative and qualitative real-world evidence to evaluate whether the routine use of e-Lung can support earlier clinical diagnosis of PPF, enabling treatment to begin sooner in the disease course, and, ultimately, support improved patient outcomes.

Dr. Michalis Papadakis, CEO and Co-Founder of Brainomix said: “We are excited to expand our strategic partnership with Boehringer Ingelheim, a recognized leader and innovator in this field, with whom we share a firm commitment to improving outcomes for people living with pulmonary fibrosis. The evidence generated to date for e-Lung is highly compelling, showing the technology has the potential to accelerate diagnosis by more than two years. This next phase will enable us to evaluate that potential at scale, providing robust real-world validation of what we expect could be a transformative advancement in the patient care pathway.”

“Boehringer Ingelheim is proud to expand our partnership with Brainomix as part of our continued commitment to improving care for people living with pulmonary fibrosis,” said Dr. Emmanuelle Clerisme-Beaty, Senior Vice President Medicine & Regulatory Affairs, Boehringer Ingelheim. “Progressive pulmonary fibrosis can be challenging to diagnose, and innovations that enhance our ability to detect disease have the potential to improve patient outcomes.”

An Innovation Hub session at ATS, entitled “Advancing ILD Care: Real-World Impact of Brainomix e-Lung,” will take place on Tuesday, May 19th, during which Prof. Peter George (Consultant Pulmonologist at the Royal Brompton Hospital, UK and Brainomix Senior Medical Director) will speak with Dr. Andy Limper (Mayo Clinic, Rochester) and Dr. Tathagat Narula (Mayo Clinic, Jacksonville) about their institution’s experience with Brainomix e-Lung, where it has been incorporated into routine clinical practice.

Brainomix will be exhibiting the e-Lung technology at the ATS International Conference (booth #2250) from Sunday, May 17th to Tuesday, May 19th.

About Brainomix

Brainomix is a global pioneer in AI medical imaging, enabling precision medicine for better treatment decisions in stroke and lung fibrosis. Its flagship product, Brainomix 360 Stroke, is the world’s first fully automated AI-imaging platform, designed for acute stroke assessment at all points of the patient pathway, facilitating more confident treatment and transfer decisions for patients in all hospitals, regardless of local resources or expertise. Brainomix 360 e-Lung technology applies AI-driven CT biomarkers to identify, monitor, and predict disease progression in pulmonary fibrosis. Founded as a spinout from the University of Oxford, Brainomix has offices in the UK, Ireland and the USA, and operations in more than 20 countries.

To learn more about Brainomix and its technology visit www.brainomix.com, and follow us on Twitter, LinkedIn, and Facebook.

Contacts

At the company
Jeff Wyrtzen, Chief Marketing Officer
jwyrtzen@brainomix.com
T +44 (0)1865 582730

Media Enquiries
USA
Jordyn Temperato
LifeSci Communications
BrainomixMedia@lifescicomms.com

UK & Europe Media Enquiries
Sue Charles
Charles Consultants
sue@charles-consultants.com

Photo : https://mma.prnewswire.com/media/2976814/Physician__Lung_Image.jpg
Logo : https://mma.prnewswire.com/media/1989193/5963053/Brainomix_Logo.jpg

1 Khor YH et al. Patient characteristics and survival for progressive pulmonary fibrosis using different definitions. Am J Respir Crit Care Med. 2023 Jan.

2 Rajan SK et al. Progressive pulmonary fibrosis: an expert group consensus statement. Eur Respir J. 2023 Mar.

View original content to download multimedia:https://www.prnewswire.com/news-releases/brainomix-and-boehringer-ingelheim-advance-strategic-partnership-in-pulmonary-fibrosis-302768599.html

SOURCE Brainomix

Related Topics:
Continue Reading

Technology

LEAP Group Relaunches HumanView, a Growth Intelligence System Built to Explain Why Customers Behave the Way They Do

Published

5 hours ago

on

October 24, 2026

By

Reimagined from the ground up, HumanView pairs statistical modeling with expert analysts to turn millions of real-world customer signals into business decisions

LOUISVILLE, Ky., Oct. 23, 2026 /PRNewswire/ — LEAP Group today announced the relaunch of HumanView, its growth intelligence service. The new version has been rebuilt from the ground up and now has a dedicated home at leapgroupnetwork.com/humanview.

HumanView analyzes what customers say and do across social platforms, e-commerce sites, review platforms, search behavior and user-generated content, including signals from Reddit, TikTok, YouTube, Meta, Amazon and Walmart+ that general AI tools cannot always access. Because the data reflects unprompted, real-world behavior, it avoids the response bias built into surveys and focus groups.

The service works in three layers. HumanView captures signals at scale, decodes millions of records through validated statistical models such as regression, correlation and clustering, and then relies on experienced analysts to interpret the patterns. Clients receive clear, human-validated insights instead of another dashboard.

“Machines find the patterns. Humans find the point,” said Alan Gilleo, CEO at LEAP Group. “The first version of HumanView showed us how much customers reveal when nobody is asking them questions. This version is built to explain why they act the way they do, and to put those answers in front of everyone making decisions, from product to service to marketing.”

HumanView focuses on three areas:

Growth Intelligence: customer motivations and how people perceive a brand and its competitors

Market and Category Intelligence: product pain points, service friction, unmet needs and competitive gaps

Audience Intelligence: new segments, positioning opportunities and gaps in the market

Every model is designed and validated by data scientists and benchmarked before it informs a recommendation.

To learn more about HumanView, visit leapgroupnetwork.com/humanview.

About LEAP Group
LEAP Group is a boutique marketing agency holding company with offices in Louisville, Indianapolis, Cincinnati and Chicago. Guided by the belief that brands should “Market Less. Matter More.,” LEAP gives clients access to specialized experts across its entire network. Learn more at leapgroupnetwork.com.

View original content to download multimedia:https://www.prnewswire.com/news-releases/leap-group-relaunches-humanview-a-growth-intelligence-system-built-to-explain-why-customers-behave-the-way-they-do-302918557.html

SOURCE LEAP Group

Continue Reading

Technology

STEPHEN A. SMITH ADDRESSES WHITE HOUSE DINNER ATTENDANCE, REAFFIRMS COMMITMENT TO HBCUs AND PROTECTING CORPORATE INVESTMENT IN BLACK EDUCATION

Published

6 hours ago

on

October 24, 2026

By

NEW YORK, Oct. 23, 2026 /PRNewswire/ — Stephen A. Smith, media mogul, New York Times bestselling author, and proud 1991 graduate of Winston-Salem State University, is addressing the public discussion surrounding his decision to attend a White House dinner with President Donald Trump, emphasizing his commitment to the long-term financial stability of Historically Black Colleges and Universities (HBCUs).

For Smith, the decision was rooted in a commitment to institutions that have educated generations of Black leaders, professionals, entrepreneurs, and public servants.

“I will always advocate for HBCUs and the students whose futures depend on them,” Smith said. “My reason for attending the White House dinner was to discuss the challenges these institutions face in securing long-term funding and to make the case that corporate America must continue to invest in them.”

Smith acknowledged federal support through the FUTURE Act while expressing concern that political tensions surrounding diversity, equity, and inclusion (DEI) could discourage private companies from supporting HBCUs. He maintains that these institutions deserve sustained corporate partnerships, philanthropic contributions, and public investment.

“If we truly believe in free-market capitalism, businesses should be able to support educational institutions and charitable causes without fear of criticism or repercussions,” Smith said. “HBCUs have made extraordinary contributions to this country. They deserve sustained public and private investment.”

Ashley Christopher, Esq., Founder and CEO of the HBCU Week Foundation, recognized Smith’s advocacy and decision to engage with the administration.

“Stephen A. Smith has been a powerful advocate for HBCUs, using his platform and influence to shine a national spotlight on our institutions,” expressed Christopher, “His continued support of HBCU Week helps advance our mission of connecting students with life-changing educational opportunities, and we are proud to have him as our ambassador.”

Since Smith became an HBCU Week Ambassador in 2019, the initiative has facilitated more than 15,000 on-the-spot college acceptances and raised and awarded more than $150 million in scholarships, according to the HBCU Week Foundation.

As public discussion continues, Smith is emphasizing the importance of ensuring HBCUs have the resources and partnerships needed to educate future generations and expand opportunities for students.

CLICK HERE to watch Smith’s full response to his White House visit.

MEDIA CONTACT:

media@mrsasinc.com

View original content:https://www.prnewswire.com/news-releases/stephen-a-smith-addresses-white-house-dinner-attendance-reaffirms-commitment-to-hbcus-and-protecting-corporate-investment-in-black-education-302918547.html

SOURCE Straight Shooter Media

Continue Reading

Technology

Advantex Announces Completion of Financing and Extension of Maturity Date of Previously Issued Debentures

Published

6 hours ago

on

October 24, 2026

By

TORONTO, Oct. 23, 2026 /CNW/ — Advantex Marketing International Inc. (CSE: ADX) (“Advantex”), a leader in the merchant cash advance and loyalty marketing products for merchants, today announced the completion of a $250,000 secured debt financing. Advantex issued a $250,000 non-convertible debenture which bears an interest rate at 12% per annum and matures December 15, 2027. The proceeds raised from this issuance of the Debenture will be used for working capital purposes.

Advantex has also extended the maturity of its existing $700,000 in 12% secured debentures from October 10, 2026 to December 15, 2027.

About Advantex Marketing International Inc.

Advantex provides working capital to merchants. Advantex also provides specialized marketing programs that enable members of Aeroplan to earn Aeroplan points at participating merchants.

Advantex shares trade on the Canadian Securities Exchange under the symbol ADX. For more information go to Advantex’s profile on www.sedar.com

Forward-Looking Information

This news release contains “forward-looking statements” within the meaning of applicable securities laws relating to the future business and operations of Advantex. Actual results and developments may differ materially from those contemplated by these statements. The business and operations of Advantex described herein is dependent on a number of factors and is subject to a number of risks and uncertainties. Factors that could cause actual results to differ material include, but are not limited to, changes in Advantex’s economic and competitive conditions including but not limited to the industry sectors in which Advantex operates.

The statements in this news release are made of the date of this release. Forward-looking statements are made based on management’s beliefs, estimates and opinions on the date the statements are made and Advantex undertakes no obligation to update forward-looking statements if these beliefs, estimates and opinions or other circumstances should change, except as required by applicable law.

SOURCE Advantex Marketing International Inc.

Continue Reading

Trending